Showing results (1-10 of 96) with videos related to
Sort By:
Pageof 10
Giornale Italiano Di Cardiologia (2006)|March 3, 2011
[Intensive glucose control in type 2 diabetes: is it harmful, needless or maybe useful in reducing cardiovascular risk?]Agostino ConsoliGiornale Italiano Di Cardiologia (2006)|February 3, 2017
[Type 2 diabetes treatment and cardiovascular risk: what can we learn from trials?]Agostino Consoli, Fabrizio FeboActa Diabetologica|February 24, 2023
Patient perceptions of insulin therapy in diabetes self-management with insulin injection devicesAgostino Consoli, Gloria FormosoExpert Opinion on Drug Safety|December 16, 2014
Potential side effects to GLP-1 agonists: understanding their safety and tolerabilityAgostino Consoli, Gloria FormosoGiornale Italiano Di Cardiologia (2006)|December 14, 2011
[Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data]Agostino Consoli, Rosamaria Di BiagioGiornale Italiano Di Cardiologia (2006)|December 24, 2013
[Anti-diabetes agents and hypoglycemia]Agostino Consoli, Patrizia Di FulvioGiornale Italiano Di Cardiologia (2006)|April 1, 2016
[Incretin therapies and multifactorial clinical approach to cardiometabolic patients]Agostino Consoli, Patrizia Di FulvioGiornale Italiano Di Cardiologia (2006)|December 22, 2012
[Towards evidence-based medicine: large-scale intervention trials with glucagon-like peptide-1 receptor agonists]Agostino Consoli, Rosamaria Di BiagioGiornale Italiano Di Cardiologia (2006)|January 28, 2015
[Cardiovascular risk reduction in the management of diabetic patients: what has changed since the '90s in the clinical approach?]Agostino Consoli, Patrizia Di FulvioDiabetes/Metabolism Research and Reviews|August 30, 2018
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?Raffaella Gentilella, Valeria Pechtner, Antonella Corcos, et al.Pageof 10